SIGA Technologies (SIGA) AI Stock Analysis

• Market Cap: $582.87M
• Dividend Yield: N/A
• Average Volume (3M): 461.52K
• Price to Earnings (P/E): 7.1
• Beta (1Y): 1.17
• Revenue Growth: 3.86%
• EPS Growth: -2.60%
• Country: US
• Employees: 46
• Sector: Healthcare
• Sector Strength: 45
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): -0.09
• Shares Outstanding: 71,606,000
• 10 Day Avg. Volume: 376,632
• 30 Day Avg. Volume: 461,516
• PEG Ratio: -0.57
• Price to Book (P/B): 1.98
• Price to Sales (P/S): 3.09
• P/FCF Ratio: 8.79
• Enterprise Value/Market Cap: 0.49
• Enterprise Value/Revenue: 1.66
• Enterprise Value/Gross Profit: 2.30
• Enterprise Value/Ebitda: 3.10
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 71 Outperform
• Price Target: $7.00 ▲(7.03% Upside)

SIGA Technologies' overall stock score is driven by its strong financial performance and undervaluation, despite technical indicators suggesting bearish momentum. The earnings call provided a mixed outlook with growth potential tempered by operational challenges.

SIGA Technologies Business Overview & Revenue Model

Company Description

SIGA Technologies, Inc. is a biotechnology company focused on developing and commercializing novel solutions for serious diseases, particularly those caused by bioterrorism and infectious diseases. The company operates primarily within the pharmaceutical sector and is known for its lead product, TPOXX (tecovirimat), which is an antiviral treatment approved for the treatment of smallpox. SIGA is also involved in research and development efforts to expand its pipeline of antiviral therapeutics.

How the Company Makes Money

SIGA Technologies generates revenue primarily through the sale of its products, notably TPOXX, which is sold to government agencies and healthcare providers for use in biodefense and public health preparedness. The company has established contracts with the U.S. government for stockpiling and procurement, which provide a significant and stable revenue stream. Additionally, SIGA may earn revenue through research and development collaborations, licensing agreements, and grants aimed at developing new antiviral therapies. Strategic partnerships with governmental and non-governmental organizations further enhance its financial stability and contribute to its earnings.

SIGA Technologies Financial Statement Overview

Summary

SIGA Technologies shows strong financial health with high profitability, a robust balance sheet with no debt, and sufficient cash flow generation. However, stagnant revenue growth and a decline in operating cash flow are areas to monitor closely for future financial performance.

Income Statement

SIGA Technologies has shown strong profitability with consistent gross and net profit margins over the years. The gross profit margin remains high at 100% in the latest year, indicating effective cost management. The net profit margin, although slightly reduced from the previous year, is still robust at 42.7%. However, the revenue growth has been stagnant, with a slight decrease of 0.9% from the prior year, which could suggest a plateau in sales expansion.

Balance Sheet

The company maintains a solid financial position with no debt, reflected in a debt-to-equity ratio of 0. The equity ratio is strong at 88.3%, indicating financial stability and a low-risk profile. Return on equity (ROE) is healthy at 27.4%, showcasing effective use of equity financing to generate profits. The absence of debt reduces financial risk significantly.

Cash Flow

Operating cash flow has decreased by 48.6% compared to the previous year, which could be a concern if the trend continues. However, free cash flow remains positive, indicating the company can cover its capital expenditures. The free cash flow to net income ratio is satisfactory, showing that profits are backed by cash generation. The decline in cash flow growth rate is a potential risk area.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	172.25M	138.72M	139.92M	110.78M	133.67M	124.96M
Gross Profit	124.60M	95.12M	122.09M	77.82M	107.13M	99.22M
EBITDA	92.43M	70.52M	84.16M	43.22M	89.62M	85.03M
Net Income	74.47M	59.21M	68.07M	33.90M	69.45M	56.34M
Balance Sheet
Total Assets	231.60M	244.34M	254.35M	195.04M	214.73M	149.83M
Cash, Cash Equivalents and Short-Term Investments	171.96M	155.40M	150.15M	98.79M	103.14M	117.89M
Total Debt	0.00	546.82K	564.01K	528.17K	466.83K	449.94K
Total Liabilities	28.12M	28.53M	57.49M	24.88M	40.41M	20.04M
Stockholders Equity	203.48M	215.80M	196.86M	170.16M	174.31M	129.79M
Cash Flow
Free Cash Flow	116.31M	48.72M	94.78M	41.61M	11.44M	71.50M
Operating Cash Flow	116.64M	48.76M	94.80M	41.61M	11.49M	71.52M
Investing Cash Flow	-332.31K	-42.45K	-21.69K	0.00	-50.62K	-15.50K
Financing Cash Flow	-43.62M	-43.46M	-43.42M	-45.96M	-26.20M	-114.60M

SIGA Technologies Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 6.54
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Positive
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SIGA, the sentiment is Negative. The current price of 6.54 is below the 20-day moving average (MA) of 8.23, below the 50-day MA of 8.55, and below the 200-day MA of 6.74, indicating a bearish trend. The MACD of -0.22 indicates Positive momentum. The RSI at 24.49 is Positive, neither overbought nor oversold. The STOCH value of 42.24 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SIGA.

SIGA Technologies Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
SIGA	71 Outperform	$582.87M	7.09	43.61%	―	3.86%	-2.60%
EBS	71 Outperform	$539.38M	7.85	13.92%	―	-29.91%	―
DVAX	58 Neutral	$1.21B	―	-7.14%	―	26.73%	-310.39%
ESPR	53 Neutral	$680.97M	―	―	―	2.83%	13.61%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
ORGO	51 Neutral	$503.63M	―	-2.64%	―	-4.21%	7.78%
AQST	45 Neutral	$725.84M	―	―	―	-26.32%	-56.54%

SIGA Technologies Corporate Events

SIGA Technologies’ Earnings Call Highlights Growth and Challenges

The recent earnings call for SIGA Technologies highlighted a generally positive sentiment, underscored by the company’s strong financial standing and growth in product sales. The call conveyed optimism driven by ongoing government contracts and international sales prospects. However, it also acknowledged challenges such as possible delays from a government shutdown, inquiries from the EMA, and inherent quarterly revenue fluctuations.

SIGA Technologies Reports Q3 2025 Financial Results

SIGA Technologies, Inc. is a commercial-stage pharmaceutical company specializing in the development of antiviral medicines to combat infectious diseases, with a primary focus on orthopoxviruses. The company is known for its flagship product, TPOXX, which is approved for the treatment of smallpox and other related diseases in various countries.